Satsuma Pharmaceuticals, Inc. 4/A SEC Filings

Filed On	Filing
09 Dec 2022	Form 4/A: Takanashi Ken, Director Granted 30,000 Stock Option (Right to Buy)
06 May 2020	Form 4/A: Albrecht Detlef, Chief Medical Officer Received 800 shares by exercise or conversion ($3.65K) · Sold 800 shares ($16K) · Disposed of 800 Stock Option (Right to Buy) (Open Market Sale)
06 May 2020	Form 4/A: Albrecht Detlef, Chief Medical Officer Received 200 shares by exercise or conversion ($912) · Sold 200 shares ($4.05K) · Disposed of 200 Stock Option (Right to Buy) (Open Market Sale)

Comments